Endometrial Cancer Clinical Trials in St Louis, Missouri

21 studies are recruiting for endometrial cancer in St Louis, Missouri right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

    This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma [cutaneous/acral], squamous cell carcinomas of the head and neck (SCCHN), HER2-negative gastric can…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Washington University, School of Medicine, St Louis, Missouri
    Locations
    90 in total
    Run by
    Daiichi Sankyo

    See if you can join NCT06172478 on ClinicalTrials.gov

  2. A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

    This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alterations.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Washington Univ. School of Medicine, St Louis, Missouri
    Locations
    20 in total
    Run by
    Terremoto Biosciences Inc.

    See if you can join NCT07109726 on ClinicalTrials.gov

  3. Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

    This protocol tests de-escalated adjuvant treatment in patients with POLE-mutated or p53wt/NSMP (p53 wildtype/no specific molecular profile) early-stage endometrial cancer (EC). Patients may be enrolled in one of two sub-studies * EN10.A/RAINBO BLUE: POLE-mutated EC * EN10.B/TAPER: p53 wildtype / N…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Washington University School of Medicine, St Louis, Missouri
    Locations
    121 in total
    Run by
    Canadian Cancer Trials Group

    See if you can join NCT05640999 on ClinicalTrials.gov

  4. A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

    This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Research Site, St Louis, Missouri
    Locations
    67 in total
    Run by
    AstraZeneca

    See if you can join NCT05123482 on ClinicalTrials.gov

  5. Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

    The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    WashU - Siteman Cancer Center, St Louis, Missouri
    Locations
    26 in total
    Run by
    SystImmune Inc.

    See if you can join NCT06293898 on ClinicalTrials.gov

  6. Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer

    The purpose of this study is to compare how well Rina-S (GEN1184) works compared to treatment of physician's choice (paclitaxel or doxorubicin) that are considered standard medical care for the treatment of recurrent or progressive endometrial cancer (EC) following prior therapy. There is an equal …

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Washington University School of Medicine, St Louis, Missouri
    Locations
    171 in total
    Run by
    Genmab

    See if you can join NCT07166094 on ClinicalTrials.gov

  7. DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

    DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progression free survival (PFS), as assessed by BICR, in participant…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Research Site, St Louis, Missouri
    Locations
    255 in total
    Run by
    AstraZeneca

    See if you can join NCT06989112 on ClinicalTrials.gov

  8. A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors

    This is a Phase 1, two-part, open-label, nonrandomized, dose-escalation and signal-seeking study of CGT6297, evaluating the safety, tolerability, PK, pharmacodynamic (what the drug does to the body), and antitumor activity of CGT6297 in adult participants with advanced solid tumors harboring PIK3CA…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Washington University School of Medicine - Siteman Cancer Center, St Louis, Missouri
    Locations
    11 in total
    Run by
    Cogent Biosciences, Inc.

    See if you can join NCT07383506 on ClinicalTrials.gov

  9. Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

    Phase I Study, a master protocol to investigate TCR-Engineered T cells recognizing KRAS mutations in adult subjects with Unresectable, Advanced, and/or Metastatic Solid Tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Research Site, St Louis, Missouri
    Locations
    18 in total
    Run by
    AstraZeneca

    See if you can join NCT06218914 on ClinicalTrials.gov

  10. A Phase 1 Study of LNCB74 in Advanced Solid Tumors

    This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Washington University, Siteman Cancer Center, St Louis, Missouri
    Locations
    14 in total
    Run by
    NextCure, Inc.

    See if you can join NCT06774963 on ClinicalTrials.gov

  11. A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

    This study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Normunity Investigational Site, St Louis, Missouri
    Locations
    18 in total
    Run by
    Normunity AccelCo, Inc.

    See if you can join NCT07182149 on ClinicalTrials.gov

  12. A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

    This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan * Learn more…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Washington University, St Louis, Missouri
    Locations
    82 in total
    Run by
    Artios Pharma Ltd

    See if you can join NCT04657068 on ClinicalTrials.gov

  13. Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

    This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-341 administered orally as a single agent or combination therapy in patients w…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Investigative Site #110, St Louis, Missouri
    Locations
    15 in total
    Run by
    MOMA Therapeutics

    See if you can join NCT06974110 on ClinicalTrials.gov

  14. Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

    This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    521, St Louis, Missouri
    Locations
    49 in total
    Run by
    Corcept Therapeutics

    See if you can join NCT06906341 on ClinicalTrials.gov

  15. Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)

    This study will collect tumor specimens with correlated clinical and demographic data from patients who are undergoing a biopsy or similar procedure to obtain tumor tissue as a normal course of their medical management or diagnostic work-up for suspected or confirmed cancer.

    Stage
    Not phased
    Ages
    18 and older
    Site
    Mercy Hospital - South, St Louis, Missouri
    Locations
    8 in total
    Run by
    Elephas

    See if you can join NCT07327489 on ClinicalTrials.gov

  16. A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

    This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune checkpoint therapy with atezolizumab in participant with recurrent and/or persistent endometrial cancer. The main protocol provides a platform for genomic screening…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Washington University School of Medicine Siteman Cancer Center, St Louis, Missouri
    Locations
    21 in total
    Run by
    Alliance Foundation Trials, LLC.

    See if you can join NCT04486352 on ClinicalTrials.gov

  17. Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors

    This first-in-human, open-label, multicenter, multi-arm dose-escalation study is designed to evaluate the safety, PK, and PD of ADU-1805, an anti- SIRPα monoclonal antibody, as monotherapy and in combination with pembrolizumab (anti-PD-1 antibody).

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Washington University Medical Campus, St Louis, Missouri
    Locations
    7 in total
    Run by
    Sairopa B.V.

    See if you can join NCT05856981 on ClinicalTrials.gov

  18. Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer

    The purpose of this study is to determine the recommended Phase 2 dose of zanzalintinib when given in combination with paclitaxel in patients with recurrent high-grade uterine cancer. Other objectives include overall safety and tolerability as well as rates of response.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Washington University School of Medicine, St Louis, Missouri
    Locations
    4 in total
    Run by
    Washington University School of Medicine

    See if you can join NCT06795009 on ClinicalTrials.gov

  19. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

    Stage
    Not phased
    Ages
    Any age
    Site
    Massive Bio SYNERGY-AI site, St Louis, Missouri
    Locations
    68 in total
    Run by
    Massive Bio, Inc.

    See if you can join NCT03452774 on ClinicalTrials.gov

  20. Mindfulness in Endometrial and Cervical Cancer

    Patients with endometrial cancer who will be undergoing surgery or patients with cervical cancer who will be treated with chemoradiation will be randomized to utilize the Headspace smartphone application or not prior to their anticipated treatment.

    Stage
    Not phased
    Ages
    18 to 90
    Site
    Saint Louis University, St Louis, Missouri
    Run by
    St. Louis University

    See if you can join NCT04512144 on ClinicalTrials.gov

  21. Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

    This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who have achieved complete response or partial response on chemotherapy. The study will be conducted in 2 parts. Part 1 will evaluate safety and efficacy of two different doses …

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Washington University School of Medicine, St Louis, Missouri
    Locations
    83 in total
    Run by
    Kartos Therapeutics, Inc.

    See if you can join NCT05797831 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.